<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954288</url>
  </required_header>
  <id_info>
    <org_study_id>AbantIBU-Biochem-OMY-2</org_study_id>
    <nct_id>NCT03954288</nct_id>
  </id_info>
  <brief_title>The Serum Sclerostin Levels in Cholesteatoma Patients</brief_title>
  <official_title>The Serum Sclerostin Levels in Cholesteatoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abant Izzet Baysal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abant Izzet Baysal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the levels of sclerostin in patients with
      cholesteatoma. So far, there is no study showing the levels of sclerostin in cholesteatoma.
      The investigators hope that the results of our study will start new processes that can be
      used in the clinic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic otitis media (COM) is the perforation of the eardrum and mucosal inflammation of the
      space in the middle ear and the air cavities of the temporal bone over a period of three
      months. Although COM is defined as a multifactorial disease, its etiopathogenesis has not
      been fully elucidated. Cholesteatoma is a condition that disrupts the balance between bone
      formation and resorption in COM. The cholesteatoma is a destructive squamous epithelial
      lesion of temporal bone, it gradually expands and leads to serious complications by the
      destruction of near bone structures, ossicular chain and otic capsule. A growing debate
      examines the role of bone formation and destruction with osteoblasts, osteocytes and
      osteoclast cells in cholesteatoma formation. Sclerostin is a glycoprotein that plays a role
      in the regulation of bone metabolism secreted by osteocytes. Antibodies directed against
      sclerostin stimulate bone formation and represent a new therapeutic option for the treatment
      of increased bone resorption diseases, such as osteoporosis and generalized bone loss,
      inflammatory diseases with cartilage damage. The aim of this study is to investigate the
      levels of sclerostin in patients with cholesteatoma. So far, there is no study showing the
      levels of sclerostin in cholesteatoma. The investigators hope that the results of our study
      will start new processes that can be used in the clinic.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>change of the levels of sclerostin in cholesteatoma at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>So far, there is no study showing the levels of sclerostin in cholesteatoma. The investigators hope that the results of our study will initiate new processes that can be used in clinical applications.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Otitis Media Chronic</condition>
  <condition>Cholesteatoma</condition>
  <arm_group>
    <arm_group_label>chronic otitis media</arm_group_label>
    <description>patients with chronic otitis media without cholesteatoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cholesteatoma</arm_group_label>
    <description>patients with chronic otitis media whose cholesteatoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>patients scheduled to operation with diagnosis of other causes</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum for sclerostin ELISA test</intervention_name>
    <description>Blood sample to measure serum sclerostin level</description>
    <arm_group_label>cholesteatoma</arm_group_label>
    <arm_group_label>chronic otitis media</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The experimental group of this study consisted of 75 patients who applied to AIBU Bolu
        Izzet Baysal Training and Research Hospital Ear Nose Throat Clinic and regularly followed
        up. A control group of approximately 50 people, which is demographically similar, and
        patients whose scheduled for operation with other causes.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        cholesteatoma chronic otitis media

        Exclusion Criteria:

        Acute infection Malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>özgür m yis</last_name>
    <phone>05324940572</phone>
    <email>dromyis@mynet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Özgür Mehmet Yis</name>
      <address>
        <city>Bolu</city>
        <state>Merkez</state>
        <zip>14100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>özgür m yis</last_name>
      <phone>5324940572</phone>
      <email>dromyis@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Abant Izzet Baysal University</investigator_affiliation>
    <investigator_full_name>Ozgur Mehmet Yis</investigator_full_name>
    <investigator_title>Assistant Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>otitis media chronic</keyword>
  <keyword>cholesteatoma</keyword>
  <keyword>sclerostin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
    <mesh_term>Cholesteatoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

